A gene-editing therapy led to durable changes in serum transthyretin levels among people with hereditary transthyretin ...

CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

If you have $200, you could invest in one of each: a well-established pharma company with a track record of billion-dollar ...

Some leading organizations in the field of cell and gene therapies recently issued a call for a 10-year international moratorium delay on the use of CRISPR. That's the scissoring techniques used to ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

Scientists developed a new nanostructure that triples CRISPR’s ability to enter cells, unlocking even more power to treat ...

A team led by scientists at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and ...

Science and medicine are incredibly amazing. Thanks to modern science and medicine, we now have lifespans far beyond our Dark ...

Budget constraints and keeping up with advancing technology are the top challenges facing European life sciences patent ...

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced longer-term follow-up data ...

In this Dylan Jovine’s Behind The Markets DNA Hacking review 2025, discover his CRISPR stock recommendation, newsletter ...

That’s why a team from UC San Diego in La Jolla set out with Yale University researchers to develop a new system for gene ...